Remdesivir.
Profiles Drug Subst Excip Relat Methodol
; 48: 71-108, 2023.
Article
in English
| MEDLINE | ID: covidwho-2227859
ABSTRACT
Remdesivir, marketed under the brand name Veklury, is an antiviral drug with a broad spectrum of activity. There were various countries where the use of Remdesivir for the treatment of COVID-19 was authorized during the pandemic. Remdesivir was first designed to treat hepatitis C, but it was later tested for Ebola virus sickness and Marburg virus infections. Remdesivir is a prodrug designed to facilitate the intracellular transport of GS-441524 monophosphate and its subsequent biotransformation into GS-441524 triphosphate, a ribonucleotide analogue inhibitor of viral RNA polymerase. The objective of this chapter is to provide a comprehensive review of Remdesivir (GS-5734), including its nomenclature, physiochemical properties, preparation methods, identification procedures, numerous qualitative and quantitative analytical techniques, ADME profiles, and pharmacological effects. In addition, the chapter provides a variety of chromatographic and spectroscopic techniques for separating brimonidine from other drugs in combination formulations.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
COVID-19
Type of study:
Qualitative research
Limits:
Humans
Language:
English
Journal:
Profiles Drug Subst Excip Relat Methodol
Year:
2023
Document Type:
Article
Affiliation country:
Bs.podrm.2022.11.003
Similar
MEDLINE
...
LILACS
LIS